Evidence map›Paper›PMID 27411697›Full record

ArticleDiabetes care2016

Changes in Mortality in People With IGT Before and After the Onset of Diabetes During the 23-Year Follow-up of the Da Qing Diabetes Prevention Study.

Qiuhong Gong, Ping Zhang, Jinping Wang, Yali An, Edward W Gregg, Hui Li, Bo Zhang, Ying Shuai, Wenying Yang, Yanyan Chen and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Dissonance in the discourse of the duration of diabetes: A mixed methods study of patient perceptions and clinical practice.Health expectations : an international journal of public participation in health care and health policy · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Qiuhong GongDepartment of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Ping ZhangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA guangwei_li@medmail.com.cn pzhang@cdc.gov.
Jinping WangDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Yali AnDepartment of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Edward W GreggDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Hui LiDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Bo ZhangDepartment of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
Ying ShuaiDepartment of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
Wenying YangDepartment of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
Yanyan ChenDepartment of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Shuqian LiuDepartment of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
Michael M EngelgauCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, Bethesda, MD.
Yinghua HuDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Peter H BennettPhoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ.
Guangwei LiDepartment of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China guangwei_li@medmail.com.cn pzhang@cdc.gov.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNChina-Japan Friendship Hospital · CNCenters for Disease Control and Prevention · USNational Heart Lung and Blood Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USTulane University · US

Funding

CDC HHS U58/CCU424123-01-02
6 · The paper itself

Abstract

objectivePeople with impaired glucose tolerance (IGT) have increased risk of mortality and a high risk of progression to diabetes, but the extent that the excess mortality is associated with IGT per se or is the result of subsequent diabetes is unclear. RESEARCH DESIGN AND

methodsWe compared mortality before and after the development of diabetes among 542 persons with IGT initially who participated in a 6-year lifestyle diabetes prevention trial and were followed-up from 1986 to 2009.

resultsDuring the 23-year follow-up, 174 (32.1%) died, with an overall death rate of 15.9/1,000 person-years. The majority of deaths (74.7%; 130 of 174) occurred after progression to type 2 diabetes, with age-adjusted death rates of 11.1/1,000 person-years (95% CI 8.2-12.0) before and 19.4/1,000 person-years (95% CI 11.9-23.3) after the development of type 2 diabetes. The cumulative mortality was 37.8% (95% CI 33.1-42.2%) in participants who developed type 2 diabetes during first 10 years of follow-up, 28.6% (95% CI 21.6-35.0%) in those who progressed to type 2 diabetes in 10-20 years, and 13.9% (95% CI 7.0-20.3%) in those who did not develop to type 2 diabetes within 20 years. Time-dependent multivariate Cox proportional hazards analyses, with adjustment for baseline age, sex, intervention, and other potential confounding risk factors, showed that the development of type 2 diabetes was associated with a 73% higher risk of death (hazard ratio 1.73 [95% CI 1.18-2.52]).

conclusionsAs elsewhere, IGT is associated with increased risk of mortality in China, but much of this excess risk is attributable to the development of type 2 diabetes.

Indexed as

ChinaDiabetes Mellitus, Type 2Disease ProgressionFemaleFollow-Up StudiesGlucose IntoleranceHumansLife StyleMaleMiddle AgedProportional Hazards ModelsRisk FactorsTime Factors

Identifiers

PMID27411697
PMCPMC5001147
OpenAlexW2472471298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.